# CB Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cb-therapeutics

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.cbthera.com
- Latest round: Series A (May 10, 2021)
- Investors on record: 2

## About

Founded in 2015 and based in California, US, CB Therapeutics Inc. is a company that develops biotechnology production methods for high-value target molecules and cannabinoids from sugar. The company was founded by its CEO Sher Ali Butt and CSO Dr.Jacob Vogan. In April 2019, CB Therapeutics Inc. raised USD 7.5 million in venture funding from unspecified investors and in May 2021, CB Therapeutics Inc. raised an undisclosed amount of Series A funding led by new investor re.Mind Capital. 

CB Therapeutics develops synthetic biology solutions to address mental health issues and increase health span. Its cellular agriculture platform specializes in the biosynthetic production of cannabinoids from sugar and other psychedelic medicines and their analogs to further clinical research for various serious health conditions. CB Therapeutics’s platform can be used to produce pure cannabinoids like CBD and THC using yeast and sugar without any plant involvement. 

The company’s pipeline is focused on the production of tryptamines, cannabinoids, and their therapeutic use in the treatment of depression, PTSD, anxiety, addiction, and other mental disorders. Using CB Therapeutics’ synthetic genomics, bioengineering, and cellular production processes, biopharmaceuticals can produce a broad range of phytochemicals faster, more sustainably, at greater yields, and with higher purity, and consistency. 

The company’s future strategy includes accelerating its manufacturing and research of cannabinoids, tryptamines, and other therapeutics.

## Funding rounds

- Series A, May 10, 2021 — re.Mind Capital
- Seed, Jul 1, 2018 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Series A